Recruiting NCT07033104
Adding Calcitonin to Bupivacaine in Transversalis Fascia Plane Block for Cesarean Section
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: us guided Transversalis fascia plane block.
- Who it may be relevant to
- Registry conditions: Transversalis Fascia Plane Block. Basic parameters: No limits · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Analgesic Effect of Adding Calcitonin to Bupivacaine in Transversalis Fascia Plane Block for Cesarean Section, A Prospective Randomized Study
Overview
Evaluate calcitonin as an adjuvant to bupivacaine in ultrasound guided tansversalis fascia plane block
Interventions
- Other us guided Transversalis fascia plane block
addition of calcitonin to pubivacaine
Primary outcome measures
- time to first rescue analgesia [Time frame: 24 hours]
Eligibility criteria
Inclusion criteria
- female pt ASA2 scheduled for cs under spinal anesthesia
Exclusion criteria
- patient refusal ASAmore than 3 patients with pregnancy related disease emergency cs history of coagulopathy
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double blind
- Primary purpose
- Prevention
Study locations
Egypt · 1 center
- tanta University hospital — Tanta
Identifiers
NCT: NCT07033104 · 36264PR1160